Payment overview · 2025
General Payments
$78.46
4 reported records · 3 companies
Healthcare provider profile · identity verified
Pixie J Plummer, MD
Allopathic & Osteopathic Physicians|Internal Medicine · BLOOMFIELD, CT · NPI 1972603793
Verified facts
What the public records show
CMS Open Payments records show Pixie J Plummer, MD received $78.46 in general payments during 2025 across 4 reported records.
Abbott Laboratories accounted for 55.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 4 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Synthroid.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 54 claims for Synthroid by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Trelegy Ellipta by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Abbott Laboratories | Unresolved — no canonical attribution shown | $43.24 | 55.1% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $19.77 | 25.2% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $15.45 | 19.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $58.48 | 3 |
| Long term medical supply or device loan | $19.98 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $23.26 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE INSULINX Normalized: freestyle insulinx |
Device | Abbott Laboratories | $19.98 | 1 | 2025 |
Source payment records
|
|||||
| SYNTHROID Normalized: synthroid |
Drug | ABBVIE INC. | $19.77 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $15.45 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| SYNTHROID synthroid |
2025 | Synthroid | 2024 | 54 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
54 | 14 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 374 | 100 |
| Amlodipine Besylate | Amlodipine Besylate | 263 | 68 |
| Levothyroxine Sodium | Levothyroxine Sodium | 223 | 54 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 166 | 47 |
| Omeprazole | Omeprazole | 134 | 32 |
| Losartan Potassium | Losartan Potassium | 123 | 34 |
| Sertraline Hcl | Sertraline Hcl | 119 | 32 |
| Hydrochlorothiazide | Hydrochlorothiazide | 110 | 31 |
| Lorazepam | Lorazepam | 110 | 25 |
| Gabapentin | Gabapentin | 105 | 31 |
| Pantoprazole Sodium | Pantoprazole Sodium | 104 | 29 |
| Lisinopril | Lisinopril | 93 | 26 |
| Metoprolol Succinate | Metoprolol Succinate | 93 | 29 |
| Trazodone Hcl | Trazodone Hcl | 90 | 22 |
| Simvastatin | Simvastatin | 86 | 23 |
| Furosemide | Furosemide | 85 | 25 |
| Metformin Hcl | Metformin Hcl | 81 | 29 |
| Ozempic | Semaglutide | 74 | 20 |
| Prednisone | Prednisone | 72 | 37 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 70 | 21 |
| Carvedilol | Carvedilol | 61 | 15 |
| Escitalopram Oxalate | Escitalopram Oxalate | 61 | 19 |
| Alprazolam | Alprazolam | 59 | 19 |
| Tramadol Hcl | Tramadol Hcl | 58 | 17 |
| Tizanidine Hcl | Tizanidine Hcl | 56 | 16 |
| Allopurinol | Allopurinol | 54 | 18 |
| Synthroid | Levothyroxine Sodium | 54 | 14 |
| Zolpidem Tartrate | Zolpidem Tartrate | 52 | 15 |
| Potassium Chloride | Potassium Chloride | 50 | suppressed |
| Xarelto | Rivaroxaban | 49 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 48 | 11 |
| Tamsulosin Hcl | Tamsulosin Hcl | 47 | 11 |
| Clonazepam | Clonazepam | 42 | 13 |
| Eliquis | Apixaban | 42 | 17 |
| Famotidine | Famotidine | 42 | 15 |
| Jardiance | Empagliflozin | 42 | 13 |
| Levetiracetam | Levetiracetam | 41 | suppressed |
| Spironolactone | Spironolactone | 38 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 37 | 13 |
| Fluticasone Propionate | Fluticasone Propionate | 36 | 17 |
| Oxycodone Hcl | Oxycodone Hcl | 36 | 16 |
| Ezetimibe | Ezetimibe | 35 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 35 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 35 | 22 |
| Valsartan | Valsartan | 35 | suppressed |
| Myrbetriq | Mirabegron | 33 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 33 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 32 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 31 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 30 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 30 | suppressed |
| Memantine Hcl | Memantine Hcl | 28 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 26 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 25 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 25 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 25 | suppressed |
| Amoxicillin | Amoxicillin | 24 | 20 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 24 | 23 |
| Fluconazole | Fluconazole | 24 | 17 |
| Nystatin | Nystatin | 24 | suppressed |
| Baclofen | Baclofen | 23 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 23 | 13 |
| Symbicort | Budesonide/Formoterol Fumarate | 23 | suppressed |
| Bupropion Xl | Bupropion Hcl | 22 | suppressed |
| Glycopyrrolate | Glycopyrrolate | 22 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 22 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 22 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 21 | suppressed |
| Meloxicam | Meloxicam | 21 | suppressed |
| Finasteride | Finasteride | 20 | suppressed |
| Mirtazapine | Mirtazapine | 20 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 20 | suppressed |
| Torsemide | Torsemide | 20 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 20 | 11 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 20 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 19 | 19 |
| Citalopram Hbr | Citalopram Hydrobromide | 18 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 18 | suppressed |
| Irbesartan | Irbesartan | 18 | suppressed |
| Azithromycin | Azithromycin | 17 | 16 |
| Doxycycline Hyclate | Doxycycline Hyclate | 17 | 14 |
| Mounjaro | Tirzepatide | 17 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 16 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 16 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 15 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 15 | suppressed |
| Pregabalin | Pregabalin | 15 | suppressed |
| Celecoxib | Celecoxib | 14 | suppressed |
| Glipizide Er | Glipizide | 14 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 14 | suppressed |
| Naltrexone Hcl | Naltrexone Hcl | 14 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 14 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 13 | suppressed |
| Januvia | Sitagliptin Phosphate | 13 | suppressed |
| Lactulose | Lactulose | 13 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 13 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 13 | suppressed |
| Ramelteon | Ramelteon | 13 | suppressed |
| Risperidone | Risperidone | 13 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 12 | suppressed |
| Cephalexin | Cephalexin | 12 | 12 |
| Ibandronate Sodium | Ibandronate Sodium | 12 | suppressed |
| Ketoconazole | Ketoconazole | 12 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 12 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 12 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 11 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 11 | suppressed |
| Sodium Chloride | Sodium Chloride Irrig Solution | 11 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $78.46 · 4 records | Abbott Laboratories | FREESTYLE INSULINX, FREESTYLE LIBRE 3, SHINGRIX, SYNTHROID | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Synthroid play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error